ClinicalTrials.gg
CompletedNCT01236118Updated May 26, 2016Results posted

A Study of LY2439821 in Rheumatoid Arthritis

A Phase 1 interventional study of LY2439821 in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Enrollment
31st of 35
28 · median 164
Started
2010
with 4 others
Phase 1
8 of 35
2 open now
Registered
12th of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 31st largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 12th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of LY2439821 subcutaneously administered for 48 weeks in Japanese participants with rheumatoid arthritis who have completed Study I1F-JE-RHAL (NCT01253265).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have received 7 injections of LY2439821 subcutaneously in the 30-, 80-, or 180-mg dose cohorts, or 11 injections in the 240-mg loading dose/120-mg once-a-week maintenance dose group, and completed the follow-up period (14 weeks) in Study I1F-JE-RHAL ((NCT01253265).
  • Ambulatory male or female participants.

    • Male participants: Agree to use a reliable method of during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing.
    • Female participants: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. Women of child bearing potential must agree to use a reliable method of birth control during the study.
  • Participants who have been treated with methotrexate (MTX) throughout Study I1F-JE-RHAL (NCT01253265). Bucillamine, sulfasalazine and/or hydroxychloroquine are allowed to be administered in addition to MTX. In such a case, the participant needs to have been on a stable dose of the drug(s) throughout Study I1F-JE-RHAL (NCT01253265) and I1F-JE-RHAM.
  • Participants who have given written approved by the Sponsor and the Institutional Review Board (IRB) governing the site.

Exclusion criteria

Exclusion Criteria:

  • Participants who have had, during Study I1F-JE-RHAL (NCT01253265), any safety event including having a recent, ongoing, or serious infection, a serious drug reaction, or any adverse event (AE) that caused discontinuation from treatment , that in the opinion of the investigator poses an unacceptable risk to participation in this study.
  • Participants who have any of the following abnormalities of clinical laboratory test results by Week 26 of Study I1F-JE-RHAL (NCT01253265):

    • \<1000 cells/microliters (μL);
    • Lymphocyte count \<500 cells/μL; or
    • White Blood Cells (WBC) count \<2000 cells/μL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    30 milligrams (mg) LY2439821

    Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).

    Drug: LY2439821

  • Experimental
    80 mg LY2439821

    Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).

    Drug: LY2439821

  • Experimental
    160 mg LY2439821

    Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.

    Drug: LY2439821

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) [Clinically Significant Events]

    Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs). A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.

    Time frame: Baseline through study completion (up to Week 56)

07

Results

Posted May 26, 2016

Participant flow

Participant flow — Overall Study
Milestone30 mg LY243982180 mg LY2439821160 mg LY2439821
Started6517
Completed4414
Not completed213
Withdrew: Adverse event202
Withdrew: Physician decision010
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) [Clinically Significant Events]

Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs). A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.

Time frame:
Baseline through study completion (up to Week 56)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) [Clinically Significant Events]
participants30 mg LY243982180 mg LY2439821160 mg LY2439821
AEs (All Causalities)6516
AEs (Drug-Related)347
SAEs102

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 mg LY2439821—1/6 (16.7%)6/6 (100%)
80 mg LY2439821—0/5 (0%)5/5 (100%)
160 mg LY2439821—2/17 (11.8%)16/17 (94.1%)
Most frequent serious events
Most frequent serious events
Event30 mg LY243982180 mg LY2439821160 mg LY2439821
Aortic dissectionVascular disorders1/60/50/17
Acute myocardial infarctionCardiac disorders0/60/51/17
CellulitisInfections and infestations0/60/51/17
Eczema infectedInfections and infestations0/60/51/17
Most frequent other events
Showing 10 of 79
Most frequent other events
Event30 mg LY243982180 mg LY2439821160 mg LY2439821
VomitingGastrointestinal disorders2/60/50/17
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/60/54/17
NasopharyngitisInfections and infestations1/60/54/17
Iron deficiency anaemiaBlood and lymphatic system disorders0/61/51/17
Injection site erythemaGeneral disorders1/61/51/17
Injection site indurationGeneral disorders0/61/51/17
GastroenteritisInfections and infestations0/61/50/17
InfluenzaInfections and infestations0/61/50/17
Systemic mycosisInfections and infestations0/61/50/17
Tinea pedisInfections and infestations0/61/51/17

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Mean53.2 ± 15.061.2 ± 8.157.6 ± 11.457.3 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Female351018
Male30710
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Hispanic or Latino0000
Not Hispanic or Latino651728
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Asian651728
Region of Enrollment
Region of Enrollment(participants)30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Japan651728
Weight
Weight(kilograms (kg))30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Mean54.23 ± 9.6954.12 ± 7.6661.25 ± 15.5558.47 ± 13.48
Height
Height(centimeters (cm))30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Mean161.62 ± 9.62152.34 ± 6.20159.52 ± 8.87158.69 ± 8.90
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))30 mg LY243982180 mg LY2439821160 mg LY2439821Total
Mean20.68 ± 2.3723.38 ± 3.5023.95 ± 5.2823.15 ± 4.60

2 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 820-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 673-1462, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 857, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Niigata, 940-2085, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 712-8044, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 152-8902, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2010
First posted
Nov 7, 2010
Start
Dec 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
May 26, 2016
Last update
May 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01236118
Responsible party
Sponsor
First posted
Nov 7, 2010
Start date
Dec 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
May 26, 2016
Last update
May 26, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion